Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/39435
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCamins, A.-
dc.contributor.authorSureda, F.X.-
dc.contributor.authorJunyent, F.-
dc.contributor.authorVerdaguer, E.-
dc.contributor.authorFolch, J.-
dc.contributor.authorBeas-Zárate, Carlos-
dc.contributor.authorPallas, M.-
dc.date.accessioned2015-09-15T17:19:00Z-
dc.date.available2015-09-15T17:19:00Z-
dc.date.issued2010-
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-77951477328&partnerID=40&md5=7987888223cc548ea3a53a3255167d8e-
dc.identifier.urihttp://hdl.handle.net/20.500.12104/39435-
dc.description.abstractImportance of the field: The increase in life expectancy in developed countries has given rise to several emerging social problems. Of particular note is the dramatic rise in the incidence of neurodegenerative diseases. Given this new social scenario, there is a need to identify therapeutic strategies to delay the advance of these pathologies, for which no effective treatment is currently available. Areas covered in this review: The present review discusses some of the drugs that are now under development with antiapoptotic activity or currently on the market that may have a potential application for the treatment of neurodegenerative diseases. Moreover, we also comment on potential compounds such as resveratrol and melatonin. Despite the lack of information from clinical trials on these two compounds, they are attracting considerable attention because of their natural origin and antioxidant and antiapoptotic action. Furthermore, they do not show toxicity in humans. In addition, we discuss the potential application of several compounds, such as NMDA antagonists, JNK inhibitors and GSK-3 inhibitors, for the treatment of neurodegenerative disorders. What the reader will gain: This article will review recent developments in the field of apoptosis inhibitors, which might provide future tools for the treatment of the neurodegenerative diseases. Take home message: The treatment of neurodegenerative diseases is a major challenge in medicine. This is partly because the incidence of these disorders is expected to rise in the coming years. New developments in the field of apoptosis inhibitors may provide future tools for the treatment of the aforementioned neurodegenerative diseases. © 2010 Informa UK Ltd.-
dc.relation.isreferencedbyScopus-
dc.relation.isreferencedbyWOS-
dc.titleAn overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders-
dc.typeReview-
dc.identifier.doi10.1517/13543781003781898-
dc.relation.ispartofjournalExpert Opinion on Investigational Drugs-
dc.relation.ispartofvolume19-
dc.relation.ispartofissue5-
dc.relation.ispartofpage587-
dc.relation.ispartofpage604-
dc.subject.keywordAlzheimer's disease; Apoptosis; Neuroprotective drugs; Parkinson's disease-
dc.contributor.affiliationCamins, A., Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Universitat de Barcelona, 08028 Barcelona, Spain; Sureda, F.X., Unitat de Farmacología, Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Universitat Rovira i Virgili, 43201 Reus (Tarragona), Spain; Junyent, F., Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Universitat de Barcelona, 08028 Barcelona, Spain, Unitat de Bioquimica, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, 43201 Reus (Tarragona), Spain; Verdaguer, E., Unitat de Bioquimica, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, 43201 Reus (Tarragona), Spain; Folch, J., Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Universitat de Barcelona, 08028 Barcelona, Spain; Beas-Zarate, C., Departamento de Biología Celular y Molecular, Universidad de Guadalajara, División de Neurociencias, Guadalajara, Jalisco 44340, Mexico; Pallas, M., Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Universitat de Barcelona, 08028 Barcelona, Spain-
dc.contributor.affiliationBeas-Zárate, Carlos., Universidad de Guadalajara. Centro Universitario de Ciencias de la Salud-
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.